What is IOVA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 6.62B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IOVA?

P/E (TTM) is n/a and 52-week range is $1.76 to $15.30 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IOVA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IOVA?

The company profile lists revenue (TTM) near $322M, net income (TTM) near $-28.72B, EPS (TTM) near $-0.72 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Iovance Biotherapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Carlos, California, US, 446.5M shares outstanding, ISIN US4622601007 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Iovance Biotherapeutics Inc

$IOVA

Health Care · Biotechnology

IR Run Scenarios

$14.62

+9.84%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 975 full-time employees. The company went IPO on 2008-06-20. The firm is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. The company is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.

Employees

975

Website

www.iovance.com/

IPO

2008-06-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)